SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Shilpa Medicare reports positive Phase 3 results for OERIS

10 Nov 2025 Evaluate

Shilpa Medicare has successfully completed its fourth complex clinical program SMLINJ011, with positive top-line Phase 3 results for its OERIS (Ondansetron Extended?Release Injection) - an innovative formulation designed to improve prophylaxis of chemotherapy?induced nausea and vomiting (CINV). Following these positive Phase 3 results, the company is preparing for regulatory submission to DCGI (Drug Controller General of India) and plans to pursue global registration and commercial partnerships through the 505(b)(2) pathway in the United States and other key markets.

Unlike existing ondansetron formulations requiring multiple daily doses or oral follow?ups, OERIS delivers sustained antiemetic coverage through a single dose that effectively addresses both acute and delayed phases of CINV for up to five days. By reducing injection frequency and simplifying dosing schedules, OERIS significantly enhances patient convenience, reduces treatment burden, and improves compliance, while optimizing healthcare workflow efficiency.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

419.90 0.75 (0.18%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×